Evidence map›Paper›PMID 36781607›Full record

ArticleMolecular biology reports2023

Morin ameliorates methotrexate-induced hepatotoxicity via targeting Nrf2/HO-1 and Bax/Bcl2/Caspase-3 signaling pathways.

Hamit Emre Kızıl, Cuneyt Caglayan, Ekrem Darendelioğlu, Adnan Ayna, Cihan Gür, Fatih Mehmet Kandemir, Sefa Küçükler

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Hamit Emre KızılVocational School of Health Sevices, Bayburt University, Bayburt, Turkey.
Cuneyt CaglayanDepartment of Medical Biochemistry, Faculty of Medicine, Bilecik Seyh Edebali University, Bilecik, Turkey. cuneyt.caglayan@bilecik.edu.tr.
Ekrem DarendelioğluDepartment of Molecular Biology and Genetics, Faculty of Science and Literature, Bingol University, 12000, Bingol, Turkey.
Adnan AynaDepartment of Chemistry, Faculty of Science and Literature, Bingol University, Bingol, Turkey.
Cihan GürDepartment of Biochemistry, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Turkey.
Fatih Mehmet KandemirDepartment of Medical Biochemistry, Faculty of Medicine, Aksaray University, Aksaray, Turkey. fkandemir03@gmail.com.ORCID http://orcid.org/0000-0002-8490-2479
Sefa KüçüklerDepartment of Biochemistry, Faculty of Veterinary Medicine, Atatürk University, Erzurum, Turkey.
Atatürk University · TRBingöl University · TRAksaray University · TRBayburt University · TRBilecik Şeyh Edebali Üniversitesi · TR

Funding

Bingöl Üniversitesi BAP-FEF.2021.006
6 · The paper itself

Abstract

backgroundOrgan toxicity limits the therapeutic efficacy of methotrexate (MTX), an anti-metabolite therapeutic that is frequently used as an anti-cancer and immunosuppressive medicine. Hepatocellular toxicity is among the most severe side effects of long-term MTX use. The present study unveils new confirmations as regards the remedial effects of morin on MTX-induced hepatocellular injury through regulation of oxidative stress, apoptosis and MAPK signaling. METHODS AND

resultsRats were subjected to oral treatment of morin (50 and 100 mg/kg body weight) for 10 days. Hepatotoxicity was induced by single intraperitoneal injection of MTX (20 mg/kg body weight) on the 5th day. MTX related hepatic injury was associated with increased MDA while decreased GSH levels, the activities of endogen antioxidants (glutathione peroxidase, superoxide dismutase and catalase) and mRNA levels of HO-1 and Nrf2 in the hepatic tissue. MTX treatment also resulted in apoptosis in the liver tissue via increasing mRNA transcript levels of Bax, caspase-3, Apaf-1 and downregulation of Bcl-2. Conversely, treatment with morin at different doses (50 and 100 mg/kg) considerably mitigated MTX-induced oxidative stress and apoptosis in the liver tissue. Morin also mitigated MTX-induced increases of ALT, ALP and AST levels, downregulated mRNA expressions of matrix metalloproteinases (MMP-2 and MMP-9), MAPK14 and MAPK15, JNK, Akt2 and FOXO1 genes.

conclusionAccording to the findings of this study, morin may be a potential way to shield the liver tissue from the oxidative damage and apoptosis.

Indexed as

Chemical and Drug Induced Liver InjuryMethotrexateAnimalsAntioxidantsbcl-2-Associated X ProteinBody WeightCaspase 3FlavonesFlavonoidsLiverNF-E2-Related Factor 2Oxidative StressRatsRats, WistarSignal TransductionAntioxidantsbcl-2-Associated X ProteinCaspase 3FlavonesFlavonoidsMethotrexatemorinNF-E2-Related Factor 2ApoptosisHepatotoxicityMethotrexateMorinOxidative stress

Identifiers

PMID36781607
OpenAlexW4320484527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.